A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

  • End date
    Dec 18, 2023
  • participants needed
  • sponsor
    Prestige Biopharma Limited
Updated on 18 June 2022
measurable disease
lung cancer
lung carcinoma
squamous non-small cell lung cancer
non-squamous non-small cell lung cancer


In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenecity.


This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).

Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between HD204 and bevacizumab.

Condition Lung Cancer, Non-small Cell Lung Cancer
Treatment carboplatin, Paclitaxel, bevacizumab, HD204
Clinical Study IdentifierNCT03390686
SponsorPrestige Biopharma Limited
Last Modified on18 June 2022


Yes No Not Sure

Inclusion Criteria

Aged ≥ 18 years
ECOG performance status of 0-1
Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung cancer
At least one measurable lesion according to RECIST v1.1
Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters

Exclusion Criteria

Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma
Sensitizing EGFR mutations or ALK rearrangements
Increased risk of bleeding determined by investigator based on radiographic / clinical findings
History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note